Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology
Ezzedine K, Vance TM, Hamzavi IH, and Qureshi AA. Vitiligo: Targeted Therapies Add Color to Disease Pathophysiology. J Invest Dermatol 2020; 140(8):1498-1500.
The Journal of investigative dermatology
There is excitement in the air for patients with vitiligo. For the first time in decades, we have early case studies showing that targeted therapies can repigment vitiliginous skin, and well-powered clinical trials are underway. However, at the time of this writing, there is no Food and Drug Administration-approved drug for vitiligo. In a randomized clinical trial by Khemis et al. report negative results on a randomized clinical trial testing the combination of apremilast, a phosphodiesterase 4 inhibitor, and narrowband-ultraviolet B versus placebo and narrowband-ultraviolet B in patients with nonsegmental vitiligo. The results of this trial are a reminder that clinical management of vitiligo is challenging at best, even when combining anti-inflammatory and/or immunomodulating agents with repigmenting agents. However, these negative trials are critical in improving our understanding of this complex and disfiguring disease.